Key Highlights
• Continued dominance of global pharmaceutical companies
• Oncology remains the leading therapeutic area
• Strong concentration in Phase II–III trials
• Early-stage trial activity shows signs of increase
• Increasing concentration in specific indications
The April 2026 data confirms that Korea continues to operate as a globally integrated clinical trial market. The high participation of multinational pharmaceutical companies indicates that Korea remains a key execution hub within global clinical development strategies, particularly in multi-regional clinical trials.
From a therapeutic perspective, oncology continues to dominate, especially in solid tumor development. This reflects Korea’s strong clinical infrastructure, experienced investigators, and reliable patient recruitment capabilities. However, the high level of competition also implies that more strategic planning in site selection and execution is required.
In terms of trial phases, Phase II and III studies remain the core. This highlights Korea’s strength as a preferred location for pivotal and confirmatory trials. Sponsors continue to prioritize Korea for its ability to deliver both high-quality data and efficient patient enrollment.
At the same time, there are emerging signals of increasing early-phase trials, including Phase I and exploratory studies. This suggests that Korea is gradually expanding its role from a late-phase execution market to an early-stage clinical validation hub.
Another notable trend is the growing concentration in specific indications. This implies that access to targeted patient populations and specialized clinical sites is becoming increasingly important, making strategic site selection a key success factor in clinical trial execution.